Ra Capital Management, L.P. - Jun 30, 2021 Form 3 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
ABOS
Transactions as of
Jun 30, 2021
Transactions value $
$0
Form type
3
Date filed
6/30/2021, 06:03 PM
Previous filing
Jun 30, 2021
Next filing
Jul 6, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABOS Series B Preferred Stock Jun 30, 2021 Common Stock 6.12M See footnotes F1, F2, F3
holding ABOS Series B Preferred Stock Jun 30, 2021 Common Stock 1.18M See footnote F1, F3, F4
holding ABOS Series B Preferred Stock Jun 30, 2021 Common Stock 589K See footnote F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series B preferred Stock has no expiration date.
F2 Shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4 Shares held directly by the Nexus Fund II.
F5 Shares held directly by the Account.